TRANSLATE

The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Why do we have low adherence to psoriasis treatments and how do we improve that?

Featured:

Steven FeldmanSteven Feldman

Sep 22, 2022


The Psoriasis and Psoriatic Arthritis Hub was pleased to speak to Steven R. Feldman, Wake Forest University, Winston-Salem, US. We asked, Why do we have low adherence to psoriasis treatments and how do we improve that?

Why do we have low adherence to psoriasis treatments and how do we improve that?

Feldman begins by pointing out that adherence to treatment is not the default and should not be assumed. It is then discussed how treatments can differ between localized and generalized psoriasis, and how doctors can increase treatment adherence in their patients.

More about...